Pharmacokinetics of anticholinergic drugs and brain muscarinic receptor alterations in streptozotocin diabetic rats

E. Nakashima, J. Ishizaki, M. Takeda, R. Matsushita, K. Yokogawa, F. Ichimura

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We studied the effects of experimental diabetes on the pharmacokinetics of biperiden (BP) and scopolamine (SP) and brain muscarinic receptor alterations in rats after the injection of streptozotocin (STZ) (60 mg kg-1 i.v.). The serum levels of BP and SP differed significantly between the rats 14 weeks after the STZ treatment and age-matched control rats. The values of total body clearance (CL(tot)) of BP and SP were significantly increased by STZ treatment. The values of volume of distribution (V(dss)) of SP were slightly increased in the STZ-treated rats, although V(dss) of BP was decreased. Because of the high lipophilicity of BP, V(dss) of BP may be decreased due to the reduced fat tissue volume caused by STZ treatment. The density of the muscarinic receptors in whole brain was measured by a radioligand receptor binding assay using [3H]-quinuclidinyl-benzylate ([3H]-QNB). The density in the diabetic rats two weeks after the STZ treatment was significantly decreased compared to age-matched control rats. However in the diabetic rats 14 weeks after the STZ treatment, there was no difference in the density of muscarinic receptors. The IC50 of muscarinic antagonist for the binding of [3H]-QNB to the receptor did not change on STZ treatment. Modulation of the receptor following repeated anticholinergic drug exposure was studied. In control rats, the number of muscarinic receptors in the brain increased by 6.9% on chronic treatment with BP for two weeks. When diabetic rats were treated with BP and SP, the number of muscarinic receptors in the brain increased by 9.6% and 33.8%, respectively.

Original languageEnglish
Pages (from-to)673-684
Number of pages12
JournalBiopharmaceutics and Drug Disposition
Volume14
Issue number8
DOIs
Publication statusPublished - 1993
Externally publishedYes

Fingerprint

Biperiden
Cholinergic Antagonists
Muscarinic Receptors
Streptozocin
Pharmacokinetics
Scopolamine Hydrobromide
Brain
Pharmaceutical Preparations
Therapeutics
Muscarinic Antagonists
Inhibitory Concentration 50
Fats

Keywords

  • Biperiden (BP)
  • Diabetic rat
  • Muscarinic receptors
  • Pharmacokinetics
  • Scopolamine (SP)

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pharmacokinetics of anticholinergic drugs and brain muscarinic receptor alterations in streptozotocin diabetic rats. / Nakashima, E.; Ishizaki, J.; Takeda, M.; Matsushita, R.; Yokogawa, K.; Ichimura, F.

In: Biopharmaceutics and Drug Disposition, Vol. 14, No. 8, 1993, p. 673-684.

Research output: Contribution to journalArticle

Nakashima, E. ; Ishizaki, J. ; Takeda, M. ; Matsushita, R. ; Yokogawa, K. ; Ichimura, F. / Pharmacokinetics of anticholinergic drugs and brain muscarinic receptor alterations in streptozotocin diabetic rats. In: Biopharmaceutics and Drug Disposition. 1993 ; Vol. 14, No. 8. pp. 673-684.
@article{a9d49a0190a54653af3fbcc83de04818,
title = "Pharmacokinetics of anticholinergic drugs and brain muscarinic receptor alterations in streptozotocin diabetic rats",
abstract = "We studied the effects of experimental diabetes on the pharmacokinetics of biperiden (BP) and scopolamine (SP) and brain muscarinic receptor alterations in rats after the injection of streptozotocin (STZ) (60 mg kg-1 i.v.). The serum levels of BP and SP differed significantly between the rats 14 weeks after the STZ treatment and age-matched control rats. The values of total body clearance (CL(tot)) of BP and SP were significantly increased by STZ treatment. The values of volume of distribution (V(dss)) of SP were slightly increased in the STZ-treated rats, although V(dss) of BP was decreased. Because of the high lipophilicity of BP, V(dss) of BP may be decreased due to the reduced fat tissue volume caused by STZ treatment. The density of the muscarinic receptors in whole brain was measured by a radioligand receptor binding assay using [3H]-quinuclidinyl-benzylate ([3H]-QNB). The density in the diabetic rats two weeks after the STZ treatment was significantly decreased compared to age-matched control rats. However in the diabetic rats 14 weeks after the STZ treatment, there was no difference in the density of muscarinic receptors. The IC50 of muscarinic antagonist for the binding of [3H]-QNB to the receptor did not change on STZ treatment. Modulation of the receptor following repeated anticholinergic drug exposure was studied. In control rats, the number of muscarinic receptors in the brain increased by 6.9{\%} on chronic treatment with BP for two weeks. When diabetic rats were treated with BP and SP, the number of muscarinic receptors in the brain increased by 9.6{\%} and 33.8{\%}, respectively.",
keywords = "Biperiden (BP), Diabetic rat, Muscarinic receptors, Pharmacokinetics, Scopolamine (SP)",
author = "E. Nakashima and J. Ishizaki and M. Takeda and R. Matsushita and K. Yokogawa and F. Ichimura",
year = "1993",
doi = "10.1002/bdd.2510140804",
language = "English",
volume = "14",
pages = "673--684",
journal = "Biopharmaceutics and Drug Disposition",
issn = "0142-2782",
publisher = "John Wiley and Sons Ltd",
number = "8",

}

TY - JOUR

T1 - Pharmacokinetics of anticholinergic drugs and brain muscarinic receptor alterations in streptozotocin diabetic rats

AU - Nakashima, E.

AU - Ishizaki, J.

AU - Takeda, M.

AU - Matsushita, R.

AU - Yokogawa, K.

AU - Ichimura, F.

PY - 1993

Y1 - 1993

N2 - We studied the effects of experimental diabetes on the pharmacokinetics of biperiden (BP) and scopolamine (SP) and brain muscarinic receptor alterations in rats after the injection of streptozotocin (STZ) (60 mg kg-1 i.v.). The serum levels of BP and SP differed significantly between the rats 14 weeks after the STZ treatment and age-matched control rats. The values of total body clearance (CL(tot)) of BP and SP were significantly increased by STZ treatment. The values of volume of distribution (V(dss)) of SP were slightly increased in the STZ-treated rats, although V(dss) of BP was decreased. Because of the high lipophilicity of BP, V(dss) of BP may be decreased due to the reduced fat tissue volume caused by STZ treatment. The density of the muscarinic receptors in whole brain was measured by a radioligand receptor binding assay using [3H]-quinuclidinyl-benzylate ([3H]-QNB). The density in the diabetic rats two weeks after the STZ treatment was significantly decreased compared to age-matched control rats. However in the diabetic rats 14 weeks after the STZ treatment, there was no difference in the density of muscarinic receptors. The IC50 of muscarinic antagonist for the binding of [3H]-QNB to the receptor did not change on STZ treatment. Modulation of the receptor following repeated anticholinergic drug exposure was studied. In control rats, the number of muscarinic receptors in the brain increased by 6.9% on chronic treatment with BP for two weeks. When diabetic rats were treated with BP and SP, the number of muscarinic receptors in the brain increased by 9.6% and 33.8%, respectively.

AB - We studied the effects of experimental diabetes on the pharmacokinetics of biperiden (BP) and scopolamine (SP) and brain muscarinic receptor alterations in rats after the injection of streptozotocin (STZ) (60 mg kg-1 i.v.). The serum levels of BP and SP differed significantly between the rats 14 weeks after the STZ treatment and age-matched control rats. The values of total body clearance (CL(tot)) of BP and SP were significantly increased by STZ treatment. The values of volume of distribution (V(dss)) of SP were slightly increased in the STZ-treated rats, although V(dss) of BP was decreased. Because of the high lipophilicity of BP, V(dss) of BP may be decreased due to the reduced fat tissue volume caused by STZ treatment. The density of the muscarinic receptors in whole brain was measured by a radioligand receptor binding assay using [3H]-quinuclidinyl-benzylate ([3H]-QNB). The density in the diabetic rats two weeks after the STZ treatment was significantly decreased compared to age-matched control rats. However in the diabetic rats 14 weeks after the STZ treatment, there was no difference in the density of muscarinic receptors. The IC50 of muscarinic antagonist for the binding of [3H]-QNB to the receptor did not change on STZ treatment. Modulation of the receptor following repeated anticholinergic drug exposure was studied. In control rats, the number of muscarinic receptors in the brain increased by 6.9% on chronic treatment with BP for two weeks. When diabetic rats were treated with BP and SP, the number of muscarinic receptors in the brain increased by 9.6% and 33.8%, respectively.

KW - Biperiden (BP)

KW - Diabetic rat

KW - Muscarinic receptors

KW - Pharmacokinetics

KW - Scopolamine (SP)

UR - http://www.scopus.com/inward/record.url?scp=0027436804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027436804&partnerID=8YFLogxK

U2 - 10.1002/bdd.2510140804

DO - 10.1002/bdd.2510140804

M3 - Article

VL - 14

SP - 673

EP - 684

JO - Biopharmaceutics and Drug Disposition

JF - Biopharmaceutics and Drug Disposition

SN - 0142-2782

IS - 8

ER -